Childress Capital Advisors’s Biogen BIIB Stock Holding History

Childress Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-58	Closed	-$14K	–	256
2020 Q4	$14K	Buy	+58	New	+$15K	0.01%	440

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Childress Capital Advisors's BIIB Position: Q1 2021 in Review

Childress Capital Advisors sold out of Biogen (BIIB) in Q1 2021, closing a stake of 58 shares — an estimated $14K sold.

Childress Capital Advisors first reported a position in BIIB in Q4 2020 and held it in 1 quarter. The position peaked at $14K in Q4 2020. 1,093 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

Childress Capital Advisors reported no remaining Biogen position as of Q1 2021 after selling out during the quarter.
Childress Capital Advisors sold 58 Biogen shares in Q1 2021, an estimated $14K.
Childress Capital Advisors first reported a position in Biogen in Q4 2020 and held it in 1 quarter.
Childress Capital Advisors's Biogen position peaked at $14K in Q4 2020.
1,093 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.